Annual report 2022

Annual report 2022*

High-precision delivery

medmix designs, develops, manufactures and delivers innovative high-precision devices and services for the mixing, application and injection of liquids in a wide range of viscosities for the healthcare, consumer and industrial end-markets. On September 30, 2021, medmix spun off from Sulzer. Its shares have since been listed and traded on the SIX Swiss Exchange in Zurich (Securities no. 112.967.710/ISIN CH1129677105).  
Read more about medmix here

* With amended chart in Corporate Governance, Board of Directors section

Letter to the shareholders 

graphic graphic

Our KEY Figures

477.1 m CHF

revenue in 2022

22.1 %

adjusted EBITDA margin

10.3 m CHF

free cash flow generated in 2022

Financial Review Section

The medmix strategy: platform for growth

graphic graphic

The medmix approach to sustainability

graphic graphic